Staphylococcus Aureus Clinical Trial
Official title:
Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration
Staphylococci represent the first etiologic agents of bone and joint infection (BJI),
leading glycopeptides use, especially in case of methicillin-resistance or betalactam
intolerance. Teicoplanin may represent an alternative to vancomycin because of its
acceptable bone penetration and possible subcutaneous administration. Various studies have
shown that teicoplanin pharmacodynamic profile was superior compared to vancomycin regarding
bone diffusion. Few studies have investigated the use of teicoplanin in BJI, particularly
through subcutaneous administration.
The aim of this study assesses the efficacy and tolerance of teicoplanin in S. aureus BJI,
especially focusing on subcutaneous use. This study is a retrospective single-center
observational cohort study (2001 to 2011) including all consecutive patients managed at our
institution receiving teicoplanin as part of S. aureus BJI treatment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05073926 -
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
|
||
Completed |
NCT01212120 -
The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections
|
N/A | |
Completed |
NCT00801879 -
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
|
Phase 4 | |
Terminated |
NCT03638947 -
Reducing Perioperative S. Aureus Transmission
|
N/A | |
Recruiting |
NCT05331885 -
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
|
Phase 3 | |
Recruiting |
NCT05094570 -
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
|
Phase 4 | |
Not yet recruiting |
NCT05092464 -
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
|
N/A | |
Recruiting |
NCT05695196 -
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04666532 -
S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
|
||
Active, not recruiting |
NCT02572791 -
Staph Household Intervention for Eradication (SHINE)
|
Phase 4 | |
Recruiting |
NCT04274348 -
Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum
|
N/A | |
Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
Completed |
NCT01011335 -
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
|
Phase 1/Phase 2 | |
Completed |
NCT03816956 -
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
|
Phase 3 | |
Not yet recruiting |
NCT04884958 -
A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
|
||
Completed |
NCT01105767 -
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
|
N/A | |
Completed |
NCT00475930 -
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates
|
N/A | |
Completed |
NCT00507247 -
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
|
Phase 2 | |
Recruiting |
NCT03220386 -
Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making
|
N/A | |
Completed |
NCT03140423 -
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
|
Phase 4 |